1189P EGFR mutation p.747_749del enhances anlotinib sensitivity by upregulating EGR1 and DUSP6 in NSCLC cells

Abstract

Lung cancer is very common and one of the leading causes of cancer mortality worldwide. Anlotinib has been widely applied to treat many types of cancers in the clinic, including NSCLC. In clinic, we found the effect of treatment with anlotinib was more significant in NSCLC with EGFR mutation p.747_749del. In this study, we have verified the hypothesis and further study its specific path which is mainly achieved by increasing the expression of the EGR1 and UBE2C genes.